PMID- 32218836
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 19
IP  - 4
DP  - 2020 Apr
TI  - PEBP4 gene expression in lung squamous cell carcinoma: A meta-analysis-based 
      study of the molecular pathways involved.
PG  - 2825-2831
LID - 10.3892/ol.2020.11386 [doi]
AB  - Previous studies have suggested increased activity of phosphatidylethanolamine 
      binding protein 4 (PEBP4) may be associated with the prognosis of non-small cell 
      lung cancer. However, to the best of our knowledge, no direct association between 
      PEBP4 and lung squamous cell carcinoma (LSCC) has been reported. In the present 
      study, a systematic review and meta-analysis was performed to examine the gene 
      expression activity of PEBP4 in LSCC. A total of 10 out of 131 gene expression 
      datasets from the Gene Expression Omnibus (GEO) were selected, including 574 
      samples (319 patients with LSCC and 255 healthy controls). Subsequently, multiple 
      linear regression (MLR) was employed to study three potential influencing 
      factors: Sample size, population region and study date. A literature-based 
      pathway analysis was then conducted to examine the potential mechanisms through 
      which PEBP4 may exert influence on LSCC. The results of a meta-analysis indicated 
      that, in LSCC, PEBP4 exhibited significantly low expression levels (P<0.033), 
      with mildly increased gene expression levels observed in three studies (log 
      fold-change: 0.072-2.13). However, a significant between-study variance was 
      observed from the heterogeneity analysis. MLR indicated that population region 
      was a significant factor (P<0.0065), whereas sample size and study age were not 
      (P>0.46). Eight functional pathways were subsequently identified, through which 
      PEBP4 may influence the prognosis of LSCC and its response to treatment. The 
      results of the present study suggested that the effects of PEBP4 on LSCC can be 
      neglected in most cases of LSCC, where PEBP4 demonstrated decreased expression 
      levels. However, in the case of PEBP4 overexpression, it may contribute to the 
      progression of LSCC and lead to the development of drug resistance.
CI  - Copyright: (c) Yu et al.
FAU - Yu, Guiping
AU  - Yu G
AD  - Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of 
      Southeast University Medical College, Jiangyin, Jiangsu 214400, P.R. China.
FAU - Zhong, Ning
AU  - Zhong N
AD  - Department of Cardiothoracic Surgery, The First People's Hospital of Kunshan, 
      Kunshan, Jiangsu 215300, P.R. China.
FAU - Huang, Bin
AU  - Huang B
AD  - Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of 
      Southeast University Medical College, Jiangyin, Jiangsu 214400, P.R. China.
FAU - Mi, Yedong
AU  - Mi Y
AD  - Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of 
      Southeast University Medical College, Jiangyin, Jiangsu 214400, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200212
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7068619
OTO - NOTNLM
OT  - gene expression
OT  - lung squamous cell carcinoma
OT  - meta-analysis
OT  - pathway analysis
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
PMCR- 2020/02/12
CRDT- 2020/03/29 06:00
PHST- 2018/07/23 00:00 [received]
PHST- 2019/05/17 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
PHST- 2020/02/12 00:00 [pmc-release]
AID - OL-0-0-11386 [pii]
AID - 10.3892/ol.2020.11386 [doi]
PST - ppublish
SO  - Oncol Lett. 2020 Apr;19(4):2825-2831. doi: 10.3892/ol.2020.11386. Epub 2020 Feb 
      12.